Real-World Use of Neratinib in Patients with HER2-Positive Early-Stage Breast Cancer Following Prior Ado-trastuzumab Emtansine (T-DM1) or Dual HER2 Blockade with Pertuzumab Plus Trastuzumab
07:30am - 03:45pm EDT - March 31, 2023
07:30am - 03:45pm EDT - March 31, 2023
Author(s):
- Kelly E. McCann, MD, UCLA Jonsson Comprehensive Cancer Center
Tags: Member Institution Clinical Oncology
| Display Label | Action |
|---|---|
| AC23P68 - Real-World Use of Neratinib in Patients with HER2-Positive Early-Stage Breast Cancer Following Prior Ado-trastuzumab Emtansine (T-DM1) or Dual HER2 Blockade with Pertuzumab Plus Trastuzumab | Download MP3 |
| 068-General Poster Session | Download Handout |
